Kalaris Therapeutics (KLRS) Capital Expenditures (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Capital Expenditures of $810000.0 for Q1 2026, up 576.47% quarter-over-quarter from -$170000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Capital Expenditures (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $810000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $810000.0; the TTM figure through Mar 2026 stood at $825000.0 (changed N/A YoY), while the FY2025 annual figure was $200000.0, down 51.22% from the prior year.
- Capital Expenditures for Q1 2026 stood at $810000.0, up from -$170000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $810000.0 in Q1 2026, with the low at -$170000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is -$17500.0 (2022), against an average of $110642.9.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures soared 707.38% in 2023, then plunged 277.08% in 2025.
- Kalaris Therapeutics' Capital Expenditures stood at -$123000.0 in 2022, then surged by 170.73% to $87000.0 in 2023, then increased by 10.34% to $96000.0 in 2024, then slumped by 277.08% to -$170000.0 in 2025, then jumped by 576.47% to $810000.0 in 2026.
- Business Quant data shows KLRS's Capital Expenditures at $810000.0 in Q1 2026, -$170000.0 in Q4 2025, and $89000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14,000.00 |
| Jun 30, 2026 | -14,000.00 |
| Mar 31, 2026 | 810,000.00 |
| Mar 31, 2026 | 810,000.00 |
| Dec 31, 2025 | -170,000.00 |
| Dec 31, 2025 | -170,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 436,000.00 |
| Sep 30, 2024 | 436,000.00 |
| Mar 31, 2024 | -122,000.00 |
| Mar 31, 2024 | -122,000.00 |
| Dec 31, 2023 | 87,000.00 |
| Dec 31, 2023 | 87,000.00 |
| Sep 30, 2023 | 741,000.00 |
| Sep 30, 2023 | 741,000.00 |
| Jun 30, 2023 | 194,000.00 |
| Jun 30, 2023 | 194,000.00 |